Author

G. M. Alicea

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Immunology· 1 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

V. W. Rebecca· 4 shared M. E. Fane· 3 shared A. Kossenkov· 2 shared A. T. Weeraratna· 2 shared D. Wirtz· 2 shared J. Villanueva· 2 shared M. E. Portuallo· 2 shared M. Herlyn· 2 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

V. W. Rebecca

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors

A. C. Johnston, G. M. Alicea, C. C. Lee, P. V. Patel, E. A. Hanna, E. Vaz, A. Forjaz, Z. Wan, P. R. Nair, Y. Lim, T. Chen, W. Du, D. Kim, T. D. Nichakawade, V. W. Rebecca, , D. Wirtz

This paper develops velocity receptors (VRs) to enhance CAR T cell migration through solid tumors, improving tumor infiltration and survival.

bioRxiv · Dec 13, 2023 · PreprintImmunology

Age-related increases in fibroblasts-secreted IGFBP2 increase melanoma cell invasion and lipid synthesis.

G. M. Alicea, M. E. Portuallo, P. Patel, M. E. Fane, A. Carey, D. W. Speicher, A. Kossenkov, V. W. Rebecca, D. Wirtz, A. T. Weeraratna

This study shows that aged fibroblasts secrete more IGFBP2, which promotes melanoma cell invasion and lipid synthesis, and that neutralizing IGFBP2 reduces tumor growth and metastasis.

bioRxiv · May 2, 2023Cancer Biology

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas

V. W. Rebecca, M. Xiao, A. Kossenkov, T. Godok, G. S. Brown, D. Fingerman, G. M. Alicea, M. Wei, H. Ji, J. Bravo, Y. Chen, M. E. Fane, J. Villanueva, K. L. Nathanson, Q. Liu, , M. Herlyn

The paper identifies dasatinib as effective in restoring BRAFi/MEKi antitumor efficacy in 70% of resistant PDX models by targeting proteins involved in therapy escape.

bioRxiv · Jan 20, 2023 · PreprintCancer Biology

Diversity, Equity, and Inclusion in the Melanoma Research Community

M. E. Portuallo, D. Y. Lu, G. M. Alicea, J. Bolling, R. Lee, J. McQuade, A. B. Warner, M. Davies, A. Weeraratna, J. Villanueva, V. W. Rebecca

The paper assesses diversity, equity, and inclusion in the melanoma research community through an international survey, revealing significant inequities related to gender, ethnicity, and geography.

bioRxiv · Sep 24, 2022Scientific Communication & Education

clampFISH 2.0 enables rapid, scalable amplified RNA detection in situ

I. Dardani, B. L. Emert, Y. Goyal, C. L. Jiang, A. Kaur, J. Lee, S. H. Rouhanifard, G. M. Alicea, M. E. Fane, M. Xiao, M. Herlyn, A. T. Weeraratna, A. Raj

clampFISH 2.0 enables rapid, scalable detection of multiple RNA species in single cells and tissue sections by improving signal amplification and reducing time and cost.

bioRxiv · Mar 16, 2022Bioengineering